Hot off the breath: 'I've a cost for' - The 64 million dollar question

Thorax

Volumn 67, Issue 5, 2012, Pages 382-384

  Bush, Andrew ^a   Simmonds, Nicholas J ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLYCINE; IVACAFTOR; LUMACAFTOR;

CF TRANSMEMBRANE REGULATOR GENE; COMMERCIAL PHENOMENA; CYSTIC FIBROSIS; DRUG COST; DRUG SAFETY; EARLY DIAGNOSIS; EDITORIAL; GENE MUTATION; GENETIC DISORDER; HEALTH CARE COST; HOMOZYGOTE; HUMAN; NEWBORN SCREENING; PRIORITY JOURNAL; PROFIT; QUALITY OF LIFE; REGULATOR GENE; RISK BENEFIT ANALYSIS; SPIROMETRY; SURVIVAL TIME;

EID: 84859846041     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-201798     Document Type: Editorial

References (14)

1. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-6. (Pubitemid 46372100)
2. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363: 1991-2003.
3. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42. (Pubitemid 24276863)
4. Elkins MR, Robinson M, Rose BR, et al National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40. (Pubitemid 43113028)
5. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002;360:978-84. (Pubitemid 35284109)
6. Saiman L, Anstead M, Mayer-Hamblett N, et al; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303:1707-15.
7. Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981;305:1489-95. (Pubitemid 12244203)
8. Mall M, Grubb BR, Harkema JR, et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-93. (Pubitemid 38667907)
9. Bush A, Lenney W, Spencer D, et al. Not NICE: a better way forward? Arch Dis Child 2011;96:907-8.
10. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008;372:1065-72.
11. Bush A, Saglani S. Management of severe asthma in children. Lancet 2010;376:814-25.
12. Bush A. Up the cystic fibrosis pulmonary creek in a barbed wire canoe. Pediatr Pulmonol 2011;(Supp 34):118-19.
13. Cantin AM, Hanrahan JW, Bilodeau G, et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006;173:1139-44. (Pubitemid 43726895)
14. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18.